In our study, we found that IL-34-stimulated FLS in RA patients could enhance the numbers of Th17 and addition of IL-6R antagonist reversed Th17 response, which indicated that the combination of IL-6/IL-6R mediated Th17 production in CD4+ T cells. Here, CD4 is linked to rheumatoid arthritis.